Exposure to antazoline-naphazoline eye drops during pregnancy and the risk of congenital malformations: A Danish nationwide cohort study
Acta Ophthalmologica Jul 15, 2019
Thomseth V, et al. - Whether an increased risk of malformations is seen, in humans, in relation to exposure to antazoline-naphazoline eye drops in the first trimester of pregnancy, was determined in this nationwide cohort study including all women giving live birth between 1997 and 2011 in Denmark. In the first trimester of pregnancy, exposure to antazoline-naphazoline eye drops was reported in overall 3061 women (0.32%). Between 1997 and 2011, a total of 977,706 births were identified. According to the findings, there appeared no link between exposure to antazoline-naphazoline eye drops in the first trimester of pregnancy and an increased teratogenic risk.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries